Shilpa Medicare share news and announcements
NSE: SHILPAMEDBSE: 530549Pharmaceuticals & BiotechnologySmall Cap
Last close ₹864.30up ₹3.50 (0.41%)BSE ₹862.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹860.80.
52-week range of traded prices to 23 Oct 2026
₹259.50Low, 27 Jan 2026₹1,095.00High, 1 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹16,904 Cr637th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 56.9
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 63.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 6.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.07%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 10.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 9,55,72541.8% delivered
Shilpa Medicare disputes and clarifications
24 filed, newest first.
Sep 2026
Jun 2026
24 Jun · Legal
Aug 2024
22 Aug · Legal
Exchange has sought clarification from Shilpa Medicare Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Mar 2023
10 Mar · Legal
The exchange asked on 9 Mar 2023
Dec 2022
24 Dec · Legal
The exchange asked on 23 Dec 2022
Aug 2022
16 Aug · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to announcement dated 11-Aug-2022 informing about Appointment.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Brief profile (in case of appointment) 2. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the company is awaited.
Jun 2022
15 Jun · Legal
The exchange asked on 14 Jun 2022
Sep 2021
6 Sep · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to announcement dated 03-Sep-2021, regarding APPOINTMENT OF INDEPENDENT DIRECTORS. On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. The response of the Company is awaited.
Jun 2021
Mar 2021
1 Mar · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to announcement dated 13-Feb-2021, regarding update on Shilpa Medicare Limited Promoted Koanna International FZ-LLC in Dubai making it as a Wholly Owned Subsidiary for the Business Operations of the Company.On basis of above the Company is required to clarify following: 1. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";2. Industry to which the entity being acquired belongs;3. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);4. Brief details of any governmental or regulatory approvals required for the acquisition;5. Cost of acquisition or the price at which the shares are acquired;6. Nature of consideration - whether cash consideration or share swap and details of the same;7. Percentage of shareholding / control acquired and / or number of shares acquired;8. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).The response of the Company is awaited.
Aug 2020
Jul 2020
30 Jul · Legal
Exchange has sought clarification from Shilpa Medicare Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Jun 2020
11 Jun · Legal
Significant movement in price has been observed in Shilpa Medicare Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Apr 2020
20 Apr · Legal
The exchange asked on 17 Apr 2020
Nov 2016
25 Nov · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to announcement dated 25-Nov-2016, regarding appointment of Mr. Rajendra Kumar Duggar, a member of ICAI and Cost Accountant as Chief Financial Officer.On basis of above the Company is required to clarify following:1. Date of appointment/cessation (as applicable) & term of appointment;2. Brief profile (in case of appointment);3. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.3 Nov · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to announcement dated 02-Nov-2016, regarding "Shilpa Medicare Limited has informed the Exchange that Koanna Healthcare Limited, UK, a wholly owned subsidiary of Shilpa Medicare Limited, INDIA has received marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) for the IMATINIB TABLETS in multiple strengths of 100 mg and 400 mg. The marketing authorization application for this generic product is made through decentralized procedure in 15 EU member states, which involves major European countries like UK, Germany, Netherlands, France, Czech Republic, Belgium, Ireland, Romania etc. Out of 15 member states the first approval is received from UK MHRA. Approvals from remaining member states will follow. ".On basis of above the Company is required to clarify following:1. Impact/relevance of such approval/license to the listed entity;2. Period for which such approval/license is/was valid;The response of the Company is awaited.
Jun 2016
8 Jun · Legal
Exchange has sought clarification from Shilpa Medicare Limited with respect to an announcement submitted to the Exchange dated May 30,2016, regarding outcome of meeting of the Board of Directors of the Company held on May 30, 2016 wherein Board of Directors has considered and approved the proposal for acquisition of 100% equity shares of Nu Therapeutics Private Limited (NTPL) in which Shilpa Medicare Limited already holds to the extent of 67.94% equity shares of the NTPL. On basis of above Company is required to clarify following -1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Nature of consideration - whether cash consideration or share swap and details of the same;4. Indicative time period for completion of the acquisition;5. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);6. Brief details of any governmental or regulatory approvals required for the acquisition;The reply from the Company is awaited.